Argos Therapeutics to Participate in the ROTH Immuno-Oncology Corporate Access Day
December 09, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Dec. 9, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
Argos Therapeutics Reports Third Quarter 2015 Financial Results and Operational Highlights
November 16, 2015 07:30 ET
|
Argos Therapeutics, Inc.
- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 -
- Established Scientific Advisory Board -
- Early stage RCC trial of AGS-003 initiated at Roswell Park Cancer...
Argos Therapeutics to Host Third Quarter 2015 Financial Results Conference Call on Monday, November 16, 2015
November 09, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
Argos Therapeutics to Participate in 3rd Annual EU Advanced Therapies Investor Day
November 06, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Nov. 6, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
Argos Therapeutics to Participate in the 3rd International mRNA Health Conference
November 05, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
Argos Therapeutics to Host Review of the Current Clinical Research Landscape in Kidney Cancer Following the 40th Congress of the European Society for Medical Oncology, With Insights From Dr. Charles Drake of Johns Hopkins Sidney Kimmel Cancer Center
October 05, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
Argos Therapeutics to Participate in 2015 Stem Cell Meeting on the Mesa
October 02, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Oct. 2, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
Robert F. Carey Appointed to the Board of Directors of Argos Therapeutics
September 23, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
Argos Therapeutics to Participate in FBR Second Annual Healthcare Conference
September 08, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
Argos Therapeutics to Participate in Stem Cells and Regenerative Medicine Congress 2015
September 01, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...